IDO1 is highly and constitutively expressed in NSCLC patients and acts as an immune checkpoint induced by potent mediators such as interferon-γ (IFN-γ), transforming growth factor-β (TGF-β), and other proinflammatory signals in the tumor microenvironment [13–16]. This evidence concerns the gene IDO1 and neoplasm.